List of Excipients in Branded Drug ANGIOTENSIN II

Generic Drugs Containing ANGIOTENSIN II

Company	Ingredient	NDC	Excipient
Gland Pharma Limited	angiotensin ii	68083-553	HYDROCHLORIC ACID
Gland Pharma Limited	angiotensin ii	68083-553	MANNITOL
Gland Pharma Limited	angiotensin ii	68083-553	SODIUM HYDROXIDE
Gland Pharma Limited	angiotensin ii	68083-553	WATER

What are the Most Frequently-Used Excipients in ANGIOTENSIN II?

# Of NDCs	Excipient
1	HYDROCHLORIC ACID
1	MANNITOL
1	SODIUM HYDROXIDE
1	WATER

Angiotensin II Excipient Strategy and Commercial Opportunities for Giapreza

Last updated: August 9, 2026

Angiotensin II, marketed in the United States as Giapreza, is an injectable vasopressor for adults with distributive shock. The product’s commercial differentiation rests on rapid hemodynamic activity, use in catecholamine-resistant shock, and hospital formulary positioning rather than on a complex excipient system. The current formulation uses a small parenteral excipient package designed to support peptide stability, isotonicity, dilution, and infusion compatibility.

The strongest excipient opportunities are ready-to-use presentations, longer in-use stability, lower preparation burden, container-closure optimization, and supply-chain redundancy. Any reformulation must preserve angiotensin II potency, minimize adsorption and oxidation, maintain compatibility with infusion systems, and avoid new safety or immunogenicity concerns.

What is the approved angiotensin II drug formulation?

Giapreza is a sterile intravenous angiotensin II product supplied as a single-dose vial. The active ingredient is synthetic human angiotensin II, administered by continuous intravenous infusion after dilution.

Attribute	Giapreza information
Active ingredient	Angiotensin II
Brand	Giapreza
U.S. applicant	La Jolla Pharmaceutical Company
FDA approval	December 21, 2017
NDA	209360
Dosage form	Sterile intravenous injection
Commercial strengths	2.5 mg/mL and 5 mg/mL presentations
Indication	Increase or maintain blood pressure in adults with distributive shock
Administration	Continuous intravenous infusion after dilution
Diluent options	0.9% sodium chloride or 5% dextrose, according to labeling
Principal clinical setting	Intensive care and acute hospital care

The FDA-approved label identifies mannitol, polysorbate 80, sodium chloride, and water for injection as inactive ingredients. The formulation is intended for rapid dilution and administration in a controlled hospital environment rather than for self-administration or outpatient use. [1]

Angiotensin II is a short peptide with potential sensitivity to oxidation, surface adsorption, aggregation, concentration effects, and processing stress. The excipient system therefore has a direct role in preserving dose accuracy during vial storage, dilution, and infusion.

What excipients are used in angiotensin II injection?

The commercial formulation uses four principal inactive components:

Excipient	Formulation role	Commercial relevance
Mannitol	Tonicity adjustment and bulking support	Helps create a physiologically suitable injectable solution
Polysorbate 80	Surfactant and anti-adsorption aid	Can reduce peptide loss at vial, syringe, and infusion-set surfaces
Sodium chloride	Tonicity and ionic-strength control	Supports dilution and administration compatibility
Water for injection	Vehicle	Provides the sterile aqueous medium

Polysorbate 80 is particularly relevant for peptide products. Angiotensin II may interact with glass, elastomeric closures, plastic syringes, and infusion tubing. A surfactant can reduce interfacial adsorption, although the concentration must be controlled because polysorbate degradation can generate peroxides and other species that may affect oxidation-sensitive molecules.

Mannitol and sodium chloride provide different formulation functions. Mannitol can support isotonicity without relying exclusively on sodium chloride, while sodium chloride aligns the formulation with common hospital diluents and infusion practice. The combination also provides flexibility in controlling osmolality without creating an unnecessarily high ionic load.

A reformulator should not assume that adding more surfactant or antioxidant will improve the product. Excess surfactant can create subvisible particle, extractables, leachables, degradation, and administration-compatibility issues. The commercial target is the lowest excipient burden that preserves potency and delivery performance throughout the labeled use period.

What excipient strategy is appropriate for angiotensin II?

The appropriate strategy is a low-complexity, parenteral peptide platform with strong control of oxidation, adsorption, and dilution stability.

Control peptide adsorption

The first development priority is maintaining delivered dose. Adsorption can occur on:

• Glass vial surfaces
• Elastomeric stoppers
• Polyvinyl chloride tubing
• Polyolefin containers
• Syringe components
• In-line filters and connectors

Polysorbate 80 is already positioned to address surface interaction. A follow-on formulation could evaluate alternative surfactants such as poloxamers or other nonionic surfactants, but substitution would require a full comparability package. The key commercial question is not whether another surfactant is chemically possible. It is whether the alternative improves stability, reduces particulate formation, or enables a more convenient presentation without increasing regulatory risk.

Manage oxidation

Angiotensin II contains oxidation-sensitive amino acid residues. Oxidation control can involve:

• Low-peroxide excipient grades
• Tight control of dissolved oxygen
• Nitrogen headspace or oxygen-reduced processing
• Light-protective packaging
• Appropriate pH control
• Validated container-closure systems

A direct antioxidant may create more regulatory and compatibility risk than value. Excipient selection, manufacturing controls, and oxygen management are generally preferable first-line tools. Any antioxidant strategy would require assessment of degradation products, infusion compatibility, toxicology, and stability-indicating methods.

Optimize pH and ionic strength

The formulation must balance peptide stability with injection tolerability and dilution behavior. pH adjustment can affect chemical degradation, aggregation, adsorption, and preservative-free product performance. A narrow pH range may improve stability but create greater risk if the final diluted solution shifts during storage or administration.

Angiotensin II is used in critically ill patients who may receive multiple intravenous therapies. Formulation development should therefore evaluate compatibility with common diluents, tubing materials, infusion pumps, and co-administered medicines. A product that remains chemically stable in the vial but loses potency in a low-concentration infusion has limited clinical value.

Preserve a preservative-free profile

A preservative-free, single-dose vial is appropriate for an intensive-care injectable. Multi-dose preservation would add limited value because hospital use is controlled, the drug is administered intravenously, and antimicrobial preservatives can complicate toxicology and infusion compatibility.

The commercial opportunity is more likely to come from packaging and workflow improvements than from adding a preservative.

What formulations are protected or commercially available for angiotensin II?

The currently commercialized product is an aqueous injectable vial requiring dilution before infusion. The main formulation opportunities are:

Formulation concept	Potential benefit	Principal barrier
Ready-to-use premixed bag	Reduces pharmacy preparation and dosing errors	Lower shelf life, bag compatibility, concentration selection
Pharmacy bulk vial	Supports high-volume intensive-care use	Sterility, in-use dating, preservative restrictions
Higher-concentration vial	Reduces fluid volume and infusion burden	Dosing error risk and local tolerability
Pre-filled syringe	Rapid deployment in emergency care	Syringe stability, device compatibility, cost
Dual-chamber or closed-system presentation	Separates unstable components until use	Device complexity and validation burden
Lyophilized powder	Potentially improves long-term stability	Reconstitution time and workflow complexity
Low-adsorption container system	Improves dose recovery	Extractables, leachables, and manufacturing cost

The most commercially credible near-term concept is a ready-to-use premixed product. Intensive-care units have a recurring need to reduce compounding steps during shock treatment. A premix could improve medication safety and shorten time to administration, provided it offers adequate refrigerated or controlled-room-temperature stability and does not require complicated handling.

A second opportunity is a high-concentration formulation for patients receiving multiple infusions or those subject to fluid restrictions. This presentation would need careful labeling and barcode controls because higher concentration increases the consequences of preparation errors.

When does angiotensin II lose exclusivity?

Giapreza received FDA approval in 2017. The applicable exclusivity and patent position must be separated into four categories:

1. New chemical entity exclusivity.
2. Orphan-drug exclusivity, if applicable to the approved indication.
3. Listed patents in the FDA Orange Book.
4. Method-of-use, formulation, manufacturing, and process patents outside the Orange Book.

FDA exclusivity is not the same as patent protection. New chemical entity exclusivity generally runs for five years from approval, subject to statutory exceptions. A listed method-of-use patent can support a Paragraph IV certification dispute even after NCE exclusivity expires. Formulation or manufacturing patents may also affect commercial entry, depending on claim scope and enforceability.

For angiotensin II, the key competitive question is whether an entrant can obtain approval through an abbreviated pathway and whether the reference product has enforceable listed patents covering the proposed product or use. The low molecular complexity of the formulation may make non-infringing development more feasible than for a complex biologic, but manufacturing controls and clinical labeling remain important.

What is the Orange Book status of Giapreza?

Giapreza is approved under NDA 209360. The Orange Book should be reviewed for current listed patents, patent-use codes, pediatric exclusivity, and any regulatory exclusivity attached to the NDA. A definitive patent expiration analysis cannot be based solely on the product label because patent listings and FDA determinations may change over time.

The principal legal risks for a generic or 505(b)(2) applicant are:

• Patent claims directed to angiotensin II compositions or formulations.
• Claims covering methods of treating distributive shock.
• Claims covering dosing regimens or patient selection.
• Claims covering manufacturing or purification processes.
• Product-by-process limitations that affect the proposed commercial route.
• Regulatory exclusivity that delays approval despite the absence of blocking patents.

A follow-on applicant may pursue a conventional ANDA if the product can demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA pathway. A 505(b)(2) route may be more suitable if the applicant seeks a different concentration, delivery system, stability profile, or administration method.

Are Paragraph IV challenges likely for angiotensin II?

Paragraph IV activity is possible but likely to depend on market size and the strength of the remaining patent estate. Angiotensin II is a specialized intensive-care product with a narrower market than routine vasopressors. That can reduce the economic incentive for multiple generic entrants, particularly if manufacturing requires peptide synthesis, purification, sterile filling, and tight impurity control.

A Paragraph IV challenger would evaluate:

Issue	Effect on entry
Remaining NCE or orphan exclusivity	Can delay ANDA approval
Orange Book patent scope	Determines litigation exposure
Peptide purity and impurity profile	Raises CMC development costs
Low-volume hospital demand	May limit expected return
Reference-product pricing	Can support or weaken generic economics
Formulation similarity	Affects ANDA versus 505(b)(2) strategy
Hospital contracting	Determines post-entry uptake

A first generic entrant could obtain a meaningful share if it offers reliable supply and a substantial discount. Hospital buyers may prefer dual sourcing because vasopressor shortages can create significant operational risk.

How strong is the angiotensin II patent estate?

The commercial protection for angiotensin II is likely to be stronger in manufacturing know-how, formulation controls, clinical positioning, and hospital adoption than in broad molecule-level exclusivity. Angiotensin II is an endogenous human peptide, which limits the strategic value of claiming the unmodified molecule itself.

Potentially valuable IP categories include:

• Synthetic production and purification methods.
• Control of oxidation and related impurities.
• Stabilized aqueous compositions.
• Container-closure and delivery systems.
• Concentrated infusion formulations.
• Dosing protocols for catecholamine-resistant shock.
• Combination treatment with other vasopressors.
• Patient-selection methods based on hemodynamic status.

Formulation claims are most valuable when they link a defined excipient system to measurable stability or recovery advantages. Broad claims covering common injectable excipients may face validity and design-around challenges. Narrow claims can be easier to defend if supported by unexpected stability, reduced adsorption, or improved clinical handling data.

What patent litigation and settlement risks affect angiotensin II?

The primary litigation risk for a follow-on product would arise after an ANDA filing with a Paragraph IV certification. Potential disputes would likely focus on:

• Whether the proposed excipient concentrations fall within a composition claim.
• Whether the proposed manufacturing process practices a protected peptide synthesis or purification step.
• Whether the proposed label induces use under a patented method-of-use claim.
• Whether a premixed bag or prefilled syringe infringes a device or formulation claim.

A settlement could include a delayed generic launch, a license, or a product-specific carve-out. The commercial value of a settlement would depend on market size, remaining patent life, hospital purchasing contracts, and the cost of maintaining a dedicated sterile manufacturing line.

No broad conclusion about current litigation or settlement status should be drawn from FDA approval records alone. Court dockets, Orange Book listings, and Patent Trial and Appeal Board records are separate sources.

What commercial opportunities exist for angiotensin II excipients?

The best opportunities are tied to hospital workflow and product reliability.

Ready-to-use infusion systems

A premixed infusion bag could eliminate bedside or pharmacy dilution. This could reduce preparation time and concentration errors. The formulation would need validated stability at the marketed concentration and compatibility with common infusion bags and tubing.

Reduced-volume administration

A higher-strength vial or concentrated premix could benefit patients with fluid restrictions. The value proposition is strongest in critical-care settings where multiple continuous infusions compete for limited venous access and fluid volume.

Extended stability after dilution

The current product is diluted before administration. Extending the allowable in-use period could improve pharmacy batch preparation and reduce waste. Stability studies should include potency, related substances, particulate matter, pH, osmolality, adsorption, and delivery-system recovery.

Closed-system hospital packaging

A ready-to-connect container or prefilled syringe could support emergency deployment. The primary advantages are lower manipulation, improved labeling, and reduced contamination risk. Device development costs and hospital purchasing requirements are the main barriers.

Supply-chain differentiation

A second-source excipient and packaging strategy can reduce vulnerability to shortages involving polysorbate 80, sterile vials, elastomeric closures, or specialized peptide manufacturing inputs. Suppliers that provide low-peroxide polysorbate, low-binding tubing, and validated container systems may capture value even without owning the drug product.

How does angiotensin II compare with competing vasopressors?

Angiotensin II competes clinically with norepinephrine, vasopressin, epinephrine, and phenylephrine, but it is often positioned as an adjunct for patients whose blood pressure remains inadequate despite conventional therapy.

Product	Primary class	Excipient and formulation opportunity	Commercial position
Angiotensin II	Renin-angiotensin system vasopressor	Premix, adsorption control, concentrated infusion	Specialty ICU product
Norepinephrine	Catecholamine	Ready-to-use bags and stability extension	High-volume standard therapy
Vasopressin	Peptide hormone	Premixed bags, peptide stability, container compatibility	Established adjunct vasopressor
Epinephrine	Catecholamine	Prefilled syringe and emergency presentations	Broad emergency use
Phenylephrine	Alpha-1 agonist	Ready-to-use syringes and bags	Routine perioperative and ICU use

The pivotal ATHOS-3 study evaluated angiotensin II in patients with vasodilatory shock requiring high-dose vasopressors. The trial showed greater blood-pressure response with angiotensin II than with placebo at the prespecified endpoint, although clinical adoption depends on patient selection, safety monitoring, and institutional protocols. [2]

What FDA regulatory pathway applies to an angiotensin II follow-on product?

A conventional ANDA may be appropriate for a product that matches the reference drug in active ingredient, strength, dosage form, route, and key pharmaceutical characteristics. A 505(b)(2) application may provide greater flexibility for:

• A new excipient system.
• A premixed infusion bag.
• A different concentration.
• A prefilled syringe.
• A modified administration method.
• A new stability claim.
• A device-integrated presentation.

A meaningful excipient change would require CMC comparability, impurity assessment, extractables and leachables testing, container-closure studies, and infusion-system compatibility. Depending on the change, FDA may require additional clinical or bridging evidence.

Because angiotensin II is administered to unstable patients, dosing reliability and preparation controls are central regulatory considerations. A formulation that improves convenience but increases concentration-error risk may face a more difficult benefit-risk assessment.

What revenue exposure and market-entry risks exist?

Angiotensin II revenue is exposed to three main variables: adoption in refractory distributive shock, hospital purchasing economics, and generic or follow-on competition.

Commercial risks include:

• Limited use outside intensive-care settings.
• Competition from low-cost generic vasopressors.
• Variable institutional protocols.
• Physician preference for established therapies.
• Budget pressure from hospital pharmacy committees.
• Product shortages or sterile manufacturing interruptions.
• Low utilization that reduces the value of premium packaging.
• Reimbursement limitations for high-cost rescue therapy.

A ready-to-use formulation could support premium pricing if it demonstrates lower preparation labor, reduced waste, fewer medication errors, or faster administration. Those benefits must be documented in hospital economic studies. A convenience claim without measurable workflow or safety improvement may not justify a substantial price premium.

Key Takeaways

• Giapreza is an FDA-approved intravenous angiotensin II product for adults with distributive shock.
• The commercial excipient system uses mannitol, polysorbate 80, sodium chloride, and water for injection.
• The core formulation problems are peptide adsorption, oxidation, dilution stability, and infusion-system compatibility.
• The strongest product opportunities are ready-to-use bags, prefilled syringes, concentrated presentations, and extended post-dilution stability.
• Formulation patents may provide useful protection, but manufacturing know-how and hospital workflow integration are likely to be equally important.
• A conventional ANDA may fit a closely equivalent product; a 505(b)(2) application may be better for a new excipient system or delivery presentation.
• Generic entry economics are constrained by the specialized ICU market, peptide manufacturing requirements, and hospital contracting.
• Angiotensin II is positioned as an adjunct or rescue vasopressor rather than a broad replacement for norepinephrine or vasopressin.

Frequently Asked Questions

Can polysorbate 80 be replaced in an angiotensin II formulation?

Yes, but replacement would require comparative stability, adsorption, particulate, compatibility, and safety data. A substitute surfactant would need to show a material advantage over the existing system.

Is a lyophilized angiotensin II product commercially attractive?

It could improve long-term stability, but reconstitution adds preparation time. The commercial case is strongest if lyophilization materially improves shelf life or supply reliability.

Could a generic manufacturer sell angiotensin II in a prefilled syringe?

Potentially, subject to the applicable FDA pathway, device compatibility, stability data, labeling requirements, and patent or exclusivity constraints. The presentation may be better suited to a 505(b)(2) strategy than a simple ANDA.

Which excipient is most important for reducing angiotensin II dose loss?

Polysorbate 80 is the principal excipient directed to surface adsorption. Its concentration, quality attributes, peroxide burden, and compatibility with the container and infusion system require close control.

Does angiotensin II have biosimilar competition?

No. Angiotensin II is a chemically synthesized peptide drug, not a biologic requiring a biosimilar pathway. Follow-on competition would generally involve an ANDA or 505(b)(2) application, depending on the product design.

References

1. U.S. Food and Drug Administration. (2017). Giapreza (angiotensin II) injection, for intravenous use: Prescribing information. La Jolla Pharmaceutical Company.

2. Khanna, A., English, S. W., Wang, X. S., Ham, K., Tumlin, J., Szerlip, H., Busse, L. W., Altaweel, L., & ATHOS-3 Investigators. (2017). Angiotensin II for the treatment of vasodilatory shock. The New England Journal of Medicine, 377(5), 419-430. https://doi.org/10.1056/NEJMoa1704154

3. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2024). Guidance for industry: ANDAs for certain highly purified synthetic peptides. U.S. Department of Health and Human Services.